Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALENE: Allogeneic hMSCs for Fistulizing Crohn's Disease
NCT02677350Phase 1Withdrawn
- Start
- Dec 2019
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of allogeneic bone marrow-derived human mesenchymal stem cells in Crohn's disease. Primary endpoint: Treatment Emergent Adverse Events at 16 months. Planned start Dec 2019; status: withdrawn.
02
Drugs
allogeneic bone marrow-derived human mesenchymal stem cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02677350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677350.